The role of regulatory T cells in ovarian cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 4, 2007, Pages 764-770

  Dietl, J ^a   Engel, J B ^a   Wischhusen, J ^b  

^a Department of Obstetrics and Gynecology ^*  (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immune escape; Ovarian cancer; Regulatory T cells; Targeted therapy; Tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE CCL22 ANTIBODY; CHEMOKINE RECEPTOR ANTAGONIST; CTLA 4 ANTIBODY; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; INTERLEUKIN 2; LYMPHOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNITY; CANCER SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE FUNCTION; MORTALITY; NONHUMAN; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

FEMALE; HUMANS; IMMUNE TOLERANCE; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 34447345986     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00861.x     Document Type: Article

References (94)

1. McGuire WP 3rd., Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003 89 (Suppl. 3 S3 8.
2. Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer. J Reprod Med 2001 46: 621 9 discussion 29-30.
3. Jazaeri AA, Awtrey CS, Chandramouli GV et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005 11: 6300 10.
4. De Smet F, Pochet NL, Engelen K et al. Predicting the clinical behavior of ovarian cancer from gene expression profiles. Int J Gynecol Cancer 2006 16 (Suppl. 1 147 51.
5. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893 105: 487 511.
6. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909 5: 273 90.
7. Burnet FM. Cancer: a biological approach. Br Med J 1957 1: 779 86.
8. Burnet FM. Immunological aspects of malignant disease. Lancet 1967 1: 1171 4.
9. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970 13: 1 2.
10. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006 24: 175 208.
11. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996 183: 725 9.
12. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005 54: 187 207.
13. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002 2: 373 82.
14. Darnell RB, Posner JB. Observing the invisible: successful tumor immunity in humans. Nat Immun 2003 4: 201.
15. Algarra I, Cabrera T, Garrido F. The HLA crossroad in tumor immunology. Hum Immunol 2000 61: 65 73.
16. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000 74: 181 273.
17. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002 12: 3 13.
18. Loeb LA, Loeb KR, Anderson JP. Multiple mutations and cancer. Proc Natl Acad Sci USA 2003 100: 776 81.
19. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immun 2002 3: 999 1005.
20. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004 22: 329 60.
21. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006 90: 1 50.
22. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006 66: 5527 36.
23. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005 8: 369 80.
24. Kryczek I, Zou L, Rodriguez P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006 203: 871 81.
25. Kryczek I, Wei S, Zou L et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006 177: 40 44.
26. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 10: 942 9.
27. Wolf D, Wolf AM, Rumpold H et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005 11: 8326 31.
28. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980 151: 69 80.
29. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313: 1960 4.
30. Schlienger K, Chu CS, Woo EY et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003 9: 1517 27.
31. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 348: 203 13.
32. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005 102: 18538 43.
33. Halpern AC, Schuchter LM. Prognostic models in melanoma. Semin Oncol 1997 24: S2 7.
34. Marrogi AJ, Munshi A, Merogi AJ et al. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997 74: 492 501.
35. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998 58: 3491 4.
36. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299: 1057 61.
37. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immun 2003 4: 330 6.
38. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immun 2003 4: 337 42.
39. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006 24: 209 26.
40. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155: 1151 64.
41. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002 2: 389 400.
42. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006 203: 1701 11.
43. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997 389: 737 42.
44. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001 182: 207 14.
45. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005 201: 1061 7.
46. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000 164: 1269 76.
47. Bellone G, Carbone A, Smirne C et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 2006 177: 3448 60.
48. Probst HC, Lagnel J, Kollias G, van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 2003 18: 713 20.
49. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002 100: 174 7.
50. Boonstra A, Asselin-Paturel C, Gilliet M et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003 197: 101 9.
51. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immun 2004 5: 516 23.
52. Cosmi L, Liotta F, Lazzeri E et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003 102: 4107 14.
53. Brenner MB, McLean J, Dialynas DP et al. Identification of a putative second T-cell receptor. Nature 1986 322: 145 9.
54. Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999 163: 242 9.
55. Gorczynski RM. Adoptive transfer of unresponsiveness to allogeneic skin grafts with hepatic gamma delta + T cells. Immunology 1994 81: 27 35.
56. Fisch P, Malkovsky M, Braakman E et al. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med 1990 171: 1567 79.
57. Ericsson PO, Hansson J, Widegren B, Dohlsten M, Sjogren HO, Hedlund G. In vivo induction of gamma/delta T cells with highly potent and selective anti-tumor cytotoxicity. Eur J Immunol 1991 21: 2797 802.
58. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005 202: 1075 85.
59. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999 163: 5211 8.
60. Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005 102: 419 24.
61. Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002 25: 207 17.
62. Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001 194: 823 32.
63. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001 61: 8643 6.
64. Ko K, Yamazaki S, Nakamura K et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005 202: 885 91.
65. Bui JD, Uppaluri R, Hsieh C-S, Schreiber RD. Comparative analysis of regulatory and effector T Cells in progressively growing versus rejecting Tumors of similar origins. Cancer Res 2006 66: 7301 09.
66. Matzinger P. The danger model: a renewed sense of self. Science 2002 296: 301 5.
67. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001 61: 4766 72.
68. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006 6: 295 307.
69. Andaloussi AE, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncol 2006 8: 234 43.
70. Woo EY, Yeh H, Chu CS et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002 168: 4272 6.
71. Raspollini MR, Castiglione F, Rossi Degl'Innocenti D et al. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005 16: 590 96.
72. Disis ML, Rivkin SE, Baron A et al. Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research Symposium. Int J Gynecol Cancer 2006 16: 463 9.
73. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001 182: 18 32.
74. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004 10: 900 1.
75. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 1988 48: 1671 5.
76. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989 49: 1649 54.
77. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005 105: 2862 8.
78. Beyer M, Kochanek M, Darabi K et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005 106: 2018 25.
79. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 2003 5: 44 51.
80. Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000 1: 110 6 discussion 17.
81. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother 2005 28: 582 92.
82. Curiel T, Barnett B, Kryczek I, Cheng P, Zou W. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Cancer Immunity 2006 6: 20.
83. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005 5: 263 74.
84. Cesana GC, DeRaffele G, Cohen S et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006 24: 1169 77.
85. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006 107: 2409 14.
86. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996 271: 1734 36.
87. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999 96: 15074 9.
88. Kocak E, Lute K, Chang X et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006 66: 7276 84.
89. Uhl M, Aulwurm S, Wischhusen J et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004 64: 7954 61.
90. Peng G, Guo Z, Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005 309: 1380 4.
91. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immun 2004 5: 508 15.
92. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004 303: 1526 9.
93. Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ. Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol 2006 27: 387 93.
94. Wang RF. Regulatory T cells and toll-like receptors in cancer therapy. Cancer Res 2006 66: 4987 90.